Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.

MLA

Ikeda, Masafumi, et al. “Efficacy and Safety of Trametinib in Japanese Patients with Advanced Biliary Tract Cancers Refractory to Gemcitabine.” Cancer Science, vol. 109, no. 1, Jan. 2018, pp. 215–24. EBSCOhost, https://doi.org/10.1111/cas.13438.

APA

Ikeda, M., Ioka, T., Fukutomi, A., Morizane, C., Kasuga, A., Takahashi, H., Todaka, A., Okusaka, T., Creasy, C. L., Gorman, S., Felitsky, D. J., Kobayashi, M., Zhang, F., & Furuse, J. (2018). Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Cancer Science, 109(1), 215–224. https://doi.org/10.1111/cas.13438

Chicago

Ikeda, Masafumi, Tatsuya Ioka, Akira Fukutomi, Chigusa Morizane, Akiyoshi Kasuga, Hideaki Takahashi, Akiko Todaka, et al. 2018. “Efficacy and Safety of Trametinib in Japanese Patients with Advanced Biliary Tract Cancers Refractory to Gemcitabine.” Cancer Science 109 (1): 215–24. doi:10.1111/cas.13438.